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Multiple myeloma (MM) is a typical disease of the elderly and in the near future physicians will 
have to treat a constantly rising number of patients who are not eligible for high-dose chemotherapy 
and autologous stem-cell transplantation, which is the standard treatment in younger fit patients. 
Elderly patients have a heterogeneous capability to resist stressors, such as MM and its treatment; 
yet the presence of comorbidities and frailty, evaluated through the geriatric assessment, can 
identify a consistent portion of frail patients (about 30% in clinical trials and about 50% in “real-
world” data) at higher risk of treatment-related toxicities and, as a consequence, at increased risk of 
disease progression and mortality (Palumbo et al, 2015). Thus, full-dose treatment in frail patients 
is often not feasible.  
In Europe, two standards of care are approved in transplant-ineligible newly diagnosed MM 
(NDMM) patients. Four 6-week twice-weekly cycles, plus five 6-week once-weekly cycles of 
bortezomib in addition to melphalan-prednisone (VMP, VISTA trial) produced a median 
progression-free survival (PFS) of 21.7 months, a median overall survival (OS) of 56.4 months, 
with 15% discontinuation rate due to adverse events, particularly due to peripheral neuropathy (San 
Miguel et al, 2013). Continuous lenalidomide 25 mg on days 1-21 in 28-day cycles with 
dexamethasone (Rd, FIRST trial) induced a median PFS of 26 months, a median OS of 59.1 
months, with 22.6% discontinuation rate (Facon et al, 2017). To further improve these results, the 
combination of bortezomib and lenalidomide has also been investigated. The SWOG-S0777 study 
compared intravenous bortezomib-lenalidomide-dexamethasone (VRd) vs standard Rd in NDMM 
patients, stratified according to the intent to transplant or not. Although VRd showed higher PFS 
(43 vs. 30 months, respectively; HR 0.712, 96% CI 0.56-0.906; p=0.0018) and also better OS (75 
vs. 64 months, respectively, HR 0.709, 95% CI 0.524-0.959; p=0.025), no ultimate conclusions 
about the treatment of elderly MM patients can be drawn, since this study was not restricted to 
elderly patients (median age 63 years) (Durie et al, 2017). Furthermore, the twice weekly 
intravenous bortezomib administration caused a higher incidence of neurological toxic effects than 
in the Rd group (33% vs 11%; p<0·0001), which led to earlier treatment discontinuation (23% vs 
10% during induction). Different trials showed that once-weekly bortezomib significantly reduced 
the incidence of severe adverse events and the rate of discontinuation due to toxicity compared with 
the twice-weekly schedule (Mateos et al, 2010; Bringhen et al, 2010). In addition, bortezomib 
administered subcutaneously showed to be as effective as the intravenous administration, combined 
with an improved safety profile, and very positive effect on patient quality of life (QoL) (Moreau et 
al, 2011). Similarly, lenalidomide plus low-dose dexamethasone was better tolerated than 
lenalidomide plus high-dose dexamethasone and proved to be even more effective (Rajkumar et al, 
2010). In relapsed and/or refractory MM patients, reduced-dose lenalidomide (15 mg for 21 days, 
every 28 days) with low-dose dexamethasone was explored (Quach et al, 2017). Median PFS was 
8.9 months and median OS was 30.5 months, not significantly different from a matched cohort of 
patients from the phase III MM009/MM010 trial, where standard dose lenalidomide and high-dose 
dexamethasone were used. On the other hand, grade 3–4 neutropenia (29% vs. 41%), infections 
(23% vs. 31%) and venous thromboembolism (3% vs. 13%) were reduced in the low-dose 
lenalidomide trial compared to the MM0009/MM010 trial. 
The combination of lenalidomide and bortezomib and the feasibility of this approach in elderly MM 
patients is still an open question. Even with the limits of the low number of patients and the design 
of the trial (absence of a comparator arm and absence of a uniform maintenance treatment), the 
paper by O’Donnell may partly answer some questions about the safety profile and the efficacy of 
this combination. This modified RVD lite regimen, including lower doses of lenalidomide (15 mg 
for 21 days/every 35 days) and weekly subcutaneous bortezomib, produced high response rate 
(86%), deep responses (very good partial response or better 66%), longer PFS (median 35.1 
months) and promising OS data, with fewer toxic effects and treatment discontinuations (4%). Of 
note, dose modifications were needed in 78% of patients, and the authors conclude that this 
preventive strategy permits patients to stay longer on treatment. Such a conservative approach 
should be suggested, in particular, in frail patients: an initial gentler therapy may be used, and 
possible dose escalations may be considered in the subsequent cycles if the treatment is optimally 
tolerated, in the absence of significant toxicities, or in case of inadequate response. Unfortunately, 
in this trial, a frailty or comorbidity evaluation was not performed, therefore, the study does not 
completely reflects a real life population, precluding meaningful considerations for frail patients. 
Nevertheless, the results of this trial support the general notion that induction with a triplet is 
beneficial also in elderly NDMM patients and can inform decision making for frontline therapy, 
particularly for fit patients. VRd lite may potentially represent a new standard of care, if results will 
be confirmed in larger well-designed trials including appropriate age and frailty stratification. In the 
future, this triplet regimen will probably be further optimized with the introduction of second-
generation new drugs. However, considering the high drug costs of novel agents, VRd regimen 
could represent a sensible/effective option for MM patients in the next years.     
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